Please use this identifier to cite or link to this item: doi:10.22028/D291-21006
Title: Serological immune response to cancer testis antigens in patients with pancreatic cancer
Author(s): Wadle, Andreas
Kubuschok, Boris
Imig, Jochen
Wuellner, Beate
Wittig, Christine
Zwick, Carsten
Mischo, Axel
Waetzig, Katrin
Romeike, Bernd F. M.
Lindemann, Werner
Schilling, Martin
Pfreundschuh, Michael
Renner, Christoph
Language: German
Year of Publication: 2006
OPUS Source: International journal of cancer. - 119. 2006, 1, S. 117-125
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Serological screening approaches have allowed for the identification of a large number of potentially relevant tumor antigens in cancer patients. Within this group, cancer testis antigens represent promising targets for cancer immunotherapy, since they are widely expressed in a variety of human cancer entities. In pancreatic cancer, however, there are only few data available about the expression pattern and serological response to cancer testis antigens and other serological-defined tumor antigens. Therefore, we investigated the IgG antibody response against 11 cancer testis antigens (SCP-1, GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5) recombinantly expressed on yeast surface (RAYS) in patients with pancreatic cancer (n = 96), chronic pancreatitis (n = 18) and healthy donors (n = 48). We found in 14% of all patients antibody responses to SCP-1, but not to other cancer testis antigens (GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5). Antibody response correlated with the expression of SCP-1 in the primary tumor of the respective patient as shown by RT-PCR, immunohistochemistry and Western blot. In contrast, no serological response to cancer testis antigens was observed in healthy donors. The humoral immune response against SCP-1 was associated with the size of tumor, but not with other clinico-pathological parameters such as histology, stage, presence of lymph node metastases, grading, age, gender or gemcitabine treatment. In conclusion, antibody response to cancer testis antigen SCP-1 is found in a proportion of pancreatic carcinoma patients. These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer.
Link to this record: urn:nbn:de:bsz:291-scidok-15384
Date of registration: 15-May-2008
Faculty: M - Medizinische Fakultät
Department: M - Innere Medizin
M - Pathologie
M - Chirurgie
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
serological_immune_response_pancreatic_cancer.pdf379,58 kBAdobe PDFView/Open

Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.